<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01428479</url>
  </required_header>
  <id_info>
    <org_study_id>115070</org_study_id>
    <nct_id>NCT01428479</nct_id>
  </id_info>
  <brief_title>Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Males</brief_title>
  <official_title>Phase1 Study of GR121167- A Double Blind, Placebo Controlled, Randomized, Dose Ascending, Single and Multiple Dose Study to Investigate the Safety and Pharmacokinetics Following Intravenous Administration of GR121167 in Healthy Japanese Males-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, ascending dose, placebo-controlled, incomplete&#xD;
      crossover, single and multiple dose study in healthy Japanese male subjects to assess the&#xD;
      pharmacokinetics and safety/tolerability of single and multiple intravenous administration of&#xD;
      GR121167. Serial blood samples and pooled urine samples for the determination of GR121167&#xD;
      concentration will be collected and safety assessments will be performed for each treatment&#xD;
      period.&#xD;
&#xD;
      The pharmacokinetics and dose proportionality of GR121167 after single intravenous&#xD;
      administration of GR121167 at the dose levels of 100 mg, 300 mg and 600 mg will be assessed.&#xD;
      In addition, in the final treatment period (600 mg), twice daily intravenous administrations&#xD;
      for 5 days will be also conducted and the pharmacokinetics and accumulation will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2011</start_date>
  <completion_date type="Actual">April 4, 2011</completion_date>
  <primary_completion_date type="Actual">April 4, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Profile of pharmacokinetics</measure>
    <time_frame>Pre, 0.5, 0.75, 1, 1.5, 2, 4, 6 ,8 ,10 ,12 ,24 hrs after single dose and 5 days multiple dose, and at the trough during multiple doses</time_frame>
    <description>Cmax, AUC0-inf, AUC0-last, AUC0-12, C12 (Cτ), accumulation ratios (Ro, Rs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>upto 24 hrs after dose and 7 days after final dose</time_frame>
    <description>vital signs, ECGs, clinical laboratory tests, and adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile of urinary pharmacokinetics</measure>
    <time_frame>0-4, 4-8, 8-12, 12-24hrs after single dose</time_frame>
    <description>Ae, fe, CLr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of serum pharmacokinetics</measure>
    <time_frame>Pre, 0.5, 0.75, 1, 1.5, 2, 4, 6 ,8 ,10 ,12 ,24 hrs after single dose and 5 days multiple dose</time_frame>
    <description>AUC0-24, %AUCex, λz, tmax, t1/2, CL, Vz, Vss</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Arm A subjects will receive 100 mg of GR121167 in Period 1 and 300 mg of GR121167 in Period 2. In Period 3 subject will receive single doses of placebo on Day 1 and multiple doses of placebo from Day 3 to Day 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Arm B subjects will receive 100 mg of GR121167 in Period 1 and placebo in Period 2. In Period 3 subject will receive 600 mg of GR121167 as single dose on Day 1 and multiple doses of GR121167 from Day 3 to Day8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Arm C subjects will receive placebo in Period 1, 300 mg of GR121167 in Period 2. In period 3 subject will receive 600 mg of GR121167 single dose on Day 1 and multiple doses from Day 3 to Day 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GR121167 Solution</intervention_name>
    <description>GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_label>Treatment Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution will be administered intravenously.</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_label>Treatment Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy as defined as being free from clinically significant illness or disease as&#xD;
             determined by a responsible and experienced physician, based on a medical evaluation&#xD;
             including medical history, physical examination, vital sign, laboratory tests and ECG.&#xD;
&#xD;
          2. Japanese healthy male between 20 and 55 years of age inclusive, at the time of signing&#xD;
             the informed consent.&#xD;
&#xD;
          3. Body weight &gt;= 50.0 kg and BMI within the range 18.5&lt;= - &lt;25.0 kg/m2 (inclusive).&#xD;
&#xD;
          4. A creatinine clearance &gt;= 80ml/min as determined by Cockcroft-Gault equation:CLcr&#xD;
             (mL/min) = (140 - age) * Wt / (72 * Scr). Where age is in years, weight (wt) is in kg,&#xD;
             and serum creatinine (Scr) is in units of mg/dl. [Cockcroft, 1976]&#xD;
&#xD;
          5. Non-smoker or ex-smoker having ceased smoking for at least 6 months.&#xD;
&#xD;
          6. AST, ALT, alkaline phosphatase and total bilirubin =&lt; ULN at screening.&#xD;
&#xD;
          7. Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A positive test for syphilis, Hepatitis B surface antigen or positive Hepatitis C&#xD;
             antibody, HIV antigen /antibody, HTLV-1 at screening&#xD;
&#xD;
          2. A positive pre-study drug screen at screening.&#xD;
&#xD;
          3. History of regular alcohol consumption exceeding, on average, 14 drinks/week for men&#xD;
             (1 drink = 5 ounces (150 mL) of wine or 350 mL of beer or 1.5 ounces (45 mL) of 80&#xD;
             proof distilled spirits) within 6 months of screening.&#xD;
&#xD;
          4. The subject had participated in a clinical study or post-marketing study with an&#xD;
             investigational or a non-investigational product during the previous 4 months&#xD;
             preceding the first dose of study medication of this study&#xD;
&#xD;
          5. The subject planned to concurrently participate in another clinical study or&#xD;
             post-marketing study.&#xD;
&#xD;
          6. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 14 days or 5 half-lives (whichever is&#xD;
             longer) prior to the first dose of study medication.&#xD;
&#xD;
          7. History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy excluding pollen allergy without current symptoms.&#xD;
&#xD;
          8. Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 400 mL within 4 month or 200 mL within 2 months.&#xD;
&#xD;
          9. Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
         10. Consumption of red wine, grapefruit or grapefruit juice from 7 days prior to the first&#xD;
             dose of study medication.&#xD;
&#xD;
         11. Single QTcB &gt;= 450 msec; at screening&#xD;
&#xD;
         12. Subjects with ECG results considered clinically significant by the investigator.&#xD;
&#xD;
         13. Subjects with a personal history of cardiac disease, symptomatic or asymptomatic&#xD;
             arrhythmias, syncopal episodes or additional risk factors for torsades de pointes&#xD;
             (e.g., heart failure, hypokalemia).&#xD;
&#xD;
         14. Subjects with a family history of sudden cardiac death.&#xD;
&#xD;
         15. Subjects with a supine systolic blood pressure &lt;90mmHg or &gt;140mmHg and/or a supine&#xD;
             diastolic blood pressure &lt;55mmHg or &gt;90mmHg and/or systolic blood pressure drop from&#xD;
             supine to standing of &gt;30mmHg.&#xD;
&#xD;
         16. History of renal failure or renal dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>September 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2011</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>115070</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115070</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115070</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115070</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115070</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115070</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

